Understand pulmonary fibrosis treatment options: A clinical guide to current care

What treatment can and cannot achieve

Understanding pulmonary fibrosis treatment options begins with recognizing that pulmonary fibrosis has no cure, and existing care generally focuses on slowing disease progression, easing symptoms, and helping a person remain active and healthy. Lung scarring is usually permanent, so treatment decisions depend on the specific type of fibrosis, its cause, the extent of lung-function impairment, and the presence of other medical conditions. 1 A specialist evaluation is important because pulmonary fibrosis includes several different interstitial lung diseases rather than one uniform condition. 2

• Idiopathic pulmonary fibrosis has no identified trigger.
• Other forms may be associated with immune diseases, medications, or inhaled toxins.
• Treatment of an underlying condition may help slow additional lung injury.

Antifibrotic medicines for progressive disease

For idiopathic pulmonary fibrosis, the principal disease-modifying medicines are nintedanib and pirfenidone. These antifibrotic therapies are used to slow the decline in lung function rather than reverse established scar tissue. Clinical guidance summarized by Medscape identifies both medicines as options for IPF and emphasizes confirming the diagnosis through an expert multidisciplinary process before treatment begins. 3 Pirfenidone and nintedanib have also been described as therapies that can slow progression and support quality of life, although they do not eliminate the disease. 5

Oxygen therapy and symptom relief

Supplemental oxygen may be prescribed when blood oxygen levels are too low, particularly during exertion or sleep. Its purpose is to maintain oxygen in a safer range and reduce symptoms related to low oxygen, but the required flow rate and delivery system must be determined by a healthcare professional. 6 The American Lung Association cautions that non-prescription portable oxygen concentrators may not meet the needs of people with pulmonary fibrosis who require prescription oxygen. 1

Symptom-focused care can also address breathlessness, persistent cough, anxiety, fatigue, and reduced activity tolerance. Harvard Health identifies oxygen and, in selected circumstances, medicines for anxiety as possible components of symptom management. 2 Oxygen equipment can affect mobility, travel, sleep, and daily routines, so ongoing assessment is needed to ensure that the prescribed system remains suitable as the disease changes.

Pulmonary rehabilitation and daily management

Pulmonary rehabilitation combines supervised exercise training, health education, and support. The aim is not to remove lung scarring, but to help a person build physical strength, improve endurance, and manage activity despite reduced lung function. Johns Hopkins describes rehabilitation as a way to learn exercises that support strength and stamina in people with pulmonary fibrosis. 8 Participation should be tailored to symptoms, oxygen requirements, cardiovascular health, and functional capacity.

• Exercise planning can help address reduced endurance.
• Education can improve understanding of oxygen use and symptom responses.
• Supportive counseling may help with the psychological effects of chronic breathlessness.
• Smoking cessation and avoidance of inhaled toxins are important non-drug measures.

Daily management also includes avoiding pulmonary irritants such as air pollution, not smoking, and maintaining routine vaccinations to reduce the risk of respiratory infections. 2 UCSF identifies smoking cessation as a critical intervention for people with interstitial lung disease. 13 These measures do not cure fibrosis, but they can reduce avoidable stress on damaged lungs and support general health.

Managing associated conditions and preventing complications

Pulmonary fibrosis often requires attention to conditions that can worsen symptoms or complicate treatment. Gastroesophageal reflux disease is common among people with pulmonary fibrosis and may contribute to lung injury, so assessment and management may be included in an individualized care plan. 9 Underlying immune diseases, including lupus, may also require effective treatment because controlling the associated disease can potentially slow the progression of lung scarring. 2

Vaccination is another preventive element of care. Influenza and pneumococcal vaccination are commonly included among recommendations intended to reduce respiratory infections that may cause serious deterioration. 11 Care teams may also monitor lung function, oxygen needs, exercise tolerance, medication effects, and acute changes in breathing. A sudden worsening of breathlessness requires medical assessment because it may reflect infection, an acute exacerbation, heart disease, or another complication rather than ordinary disease progression.

Transplantation, trials, and supportive care

Lung transplantation is a surgical option for some people with advanced pulmonary fibrosis, but it is not appropriate for everyone. Candidates must meet strict medical criteria, and assessment can involve disease severity, overall health, other illnesses, functional status, and the ability to manage the long-term requirements of transplantation. 7 Because donor availability, surgical risk, and post-transplant care create substantial limitations, referral and evaluation are separate from guaranteed eligibility.

Clinical trials may provide access to investigational therapies for idiopathic pulmonary fibrosis and other fibrosing lung diseases. The Pulmonary Fibrosis Foundation identifies research participation as a pathway for studying emerging treatments, but experimental therapies may have unknown risks and are governed by research protocols and regulatory oversight. 10 Palliative care can be integrated at any stage to help relieve breathlessness and anxiety while providing psychological and family support. 12 It is supportive care, not an indication that disease-directed treatment has ended.

How treatment choices are monitored

Treatment selection is not a one-time decision. Antifibrotic therapy requires attention to side effects, liver function, medication interactions, and tolerance, while oxygen and rehabilitation plans may need adjustment as activity levels and oxygen requirements change. Guidance summarized by Medscape advises caution with liver impairment and recommends managing gastrointestinal effects and photosensitivity proactively. 3 Patients should discuss persistent diarrhea, severe nausea, unusual fatigue, jaundice, worsening rash, or a marked change in breathing with the treating team.

Progression can occur despite treatment, and no current therapy reliably reverses established fibrosis. 2 For that reason, care commonly combines disease-modifying treatment when appropriate with rehabilitation, infection prevention, symptom control, psychosocial support, and consideration of transplantation or research participation. The relevant balance depends on diagnosis, disease behavior, organ function, risks, personal goals, and access to an interstitial lung disease specialist.

Sources

1. American Lung Association, “How Is Pulmonary Fibrosis Treated?” https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/how-is-pulmonary-fibrosis-treated
2. Harvard Health, “Pulmonary Fibrosis” https://www.health.harvard.edu/respiratory-health/what-is-pulmonary-fibrosis-and-how-is-it-treated
3. Medscape, “Treatment of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis” https://reference.medscape.com/cc2/p10/idiopathic-pulmonary-fibrosis-and-progressive-guideline-2026a1000al4
4. Lung Foundation Australia, “Pulmonary Fibrosis Treatment” https://lungfoundation.com.au/lung-diseases/pulmonary-fibrosis/treatment/
5. U.S. Pharmacist, “Optimizing Idiopathic Pulmonary Fibrosis Management” https://www.uspharmacist.com/article/optimizing-idiopathic-pulmonary-fibrosis-management-1
6. Mayo Clinic, “Pulmonary Fibrosis: Diagnosis and Treatment” https://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/diagnosis-treatment/drc-20353696
7. Cleveland Clinic, “Pulmonary Fibrosis” https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis
8. Johns Hopkins Medicine, “Pulmonary Fibrosis” https://www.hopkinsmedicine.org/health/conditions-and-diseases/pulmonary-fibrosis
9. National Heart, Lung, and Blood Institute, “Pulmonary Fibrosis Treatment” https://www.nhlbi.nih.gov/health/pulmonary-fibrosis/treatment
10. Pulmonary Fibrosis Foundation, “Treating PF” https://www.pulmonaryfibrosis.org/patients/about-pf/treating-pf
11. WebMD, “Understanding Pulmonary Fibrosis Treatment” https://www.webmd.com/lung/understanding-pulmonary-fibrosis-treatment
12. MedlinePlus, “Pulmonary Fibrosis” https://medlineplus.gov/genetics/condition/pulmonary-fibrosis/
13. UCSF Health, “Pulmonary Fibrosis: Treatment” https://www.ucsfhealth.org/conditions/pulmonary-fibrosis/treatment